Dual-specificity PPARα/γ agonist (IC50 values are 0.35 and 3.8 μM for PPARγ and PPARα respectively). Prevents atherosclerosis progression in E3L.CETP transgenic mice. Also reduces insulin resistance in obese Zucker rats. Orally active.
Sold with the permission of AstraZeneca UK Ltd.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 408.47. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.45 mL||12.24 mL||24.48 mL|
|5 mM||0.49 mL||2.45 mL||4.9 mL|
|10 mM||0.24 mL||1.22 mL||2.45 mL|
|50 mM||0.05 mL||0.24 mL||0.49 mL|
References are publications that support the biological activity of the product.
Cronet et al (2001) Structure of the PPARβ and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9 699 PMID: 11587644
Ljung et al (2002) AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J.Lipid Res. 43 1855 PMID: 12401884
Ebdrup et al (2003) Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar. J.Med.Chem. 46 1306 PMID: 12672231
van der Hoorn et al (2009) The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br.J.Pharmacol. 156 1067 PMID: 19220285
If you know of a relevant reference for Tesaglitazar, please let us know.
View Related Products by Product Action
Keywords: Tesaglitazar, Tesaglitazar supplier, AZ242, peroxisome, proliferator, activated, receptors, ppars, ppara, pparalpha, pparα, pparg, ppargamma, pparγ, agonists, astrazeneca, AZ, 242, Non-selective, PPAR, 3965, Tocris Bioscience
Citations for Tesaglitazar
Citations are publications that use Tocris products.
Currently there are no citations for Tesaglitazar. Do you know of a great paper that uses Tesaglitazar from Tocris? Please let us know.
Reviews for Tesaglitazar
Average Rating: 5 (Based on 1 Review.)
Have you used Tesaglitazar?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
HL-1 cardiomyocytes were incubated with Tesaglitazar (10 µM) for 30 min prior to addition of 15 µM 15d-PGJ2 for 30 min. Preincubation of cells with Tesaglitazar completely abolished activation of p42/44 MAPK indicating involvement of PPAR gamma in cellular signalling in response to 15d-PGJ2.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.